Zobrazeno 1 - 10
of 1 822
pro vyhledávání: '"stereotactic ablative radiotherapy"'
Autor:
G. A. Panshin, N. V. Nudnov
Publikováno v:
Вестник рентгенологии и радиологии, Vol 105, Iss 2, Pp 107-113 (2024)
Diagnostic imaging of oligometastatic disease is a difficult task, since it requires determining the exact locoregional stage of the underlying disease and assessing the condition of the entire body in terms of possible diffuse spread of distant meta
Externí odkaz:
https://doaj.org/article/f54dfa7ecd10454c809b3f86c94e8a7f
Autor:
David A. Palma, Meredith E. Giuliani, Rohann J. M. Correa, Famke L. Schneiders, Stephen Harrow, Matthias Guckenberger, Tina Zhang, Houda Bahig, Sashendra Senthi, Peter Chung, Robert Olson, Michael Lock, Srinivas Raman, Glenn S. Bauman, Benjamin H. Lok, Joanna M. Laba, Rachel M. Glicksman, Timothy K. Nguyen, Pencilla Lang, Joelle Helou, Christopher D. Goodman, Lucas C. Mendez, Peter S. N. van Rossum, Andrew Warner, Stewart Gaede, Alison L. Allan
Publikováno v:
BMC Palliative Care, Vol 23, Iss 1, Pp 1-15 (2024)
Abstract Background Emerging randomized data, mostly from phase II trials, have suggested that patients with oligometastatic cancers may benefit from ablative treatments such as stereotactic ablative radiotherapy (SABR). However, phase III data testi
Externí odkaz:
https://doaj.org/article/2b8baa340960407cab86422d2a88489d
Autor:
Hung‐Jen Chen, Wen‐Chien Cheng, Chih‐Yen Tu, Te‐Chun Hsia, Yu‐Sen Lin, Hsin‐Yuan Fang, Chia‐Chin Li, Chun‐Ru Chien
Publikováno v:
Thoracic Cancer, Vol 15, Iss 24, Pp 1779-1791 (2024)
Abstract Introduction The use of stereotactic ablative radiotherapy (SABR) over conventional fractionated radiotherapy (CFRT) for early‐stage non‐small‐cell lung cancer (NSCLC) has been advocated, but is also debated in the literature. Methods
Externí odkaz:
https://doaj.org/article/b5a1df5980e245789315c493f66a336b
Autor:
Alan Wigg, Jonathan Tibballs, Richard Woodman, Katherine Stuart, Hien Le, Stuart K. Roberts, John K. Olynyk, Simone I. Strasser, Michael Wallace, Jarad Martin, Annette Haworth, Nicholas Hardcastle, Kee Fong Loo, Colin Tang, Yoo Young Lee, Julie Chu, Richard De Abreu Lourenco, Adam Koukourou, Diederick De Boo, Kate McLean, Jackie Buck, Rohit Sawhney, Amanda Nicoll, Anouk Dev, Marnie Wood, Alicia Braund, Martin Weltman, Richard Khor, Miriam Levy, Tim Wang, Michael Potter, James Haridy, Ashok Raj, Oliver Duncan, Amany Zekry, Natalie Collier, James O’Beirne, Catherine Holliday, Yuvnik Trada, Jaw Tronidjaja, Jacob George, David Pryor
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Therapeutic options for early-stage hepatocellular carcinoma (HCC) in individual patients can be limited by tumor and location, liver dysfunction and comorbidities. Many patients with early-stage HCC do not receive curative-intent
Externí odkaz:
https://doaj.org/article/6d523d1c82814f78b6224ff1b323717f
Publikováno v:
Precision Radiation Oncology, Vol 8, Iss 2, Pp 85-91 (2024)
Abstract Lung oligometastases represent an intermediate state of cancer dissemination between localized and widespread metastases. Stereotactic body radiation therapy (SBRT) has emerged as an effective treatment option, with an efficacy comparable to
Externí odkaz:
https://doaj.org/article/1bb7d0e0008049ec8621ef58e2c895e7
Autor:
Carolin Buchele, C. Katharina Renkamp, Sebastian Regnery, Rouven Behnisch, Carolin Rippke, Fabian Schlüter, Philipp Hoegen-Saßmannshausen, Jürgen Debus, Juliane Hörner-Rieber, Markus Alber, Sebastian Klüter
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-11 (2024)
Abstract Introduction Magnetic resonance guided radiotherapy (MRgRT) allows daily adaptation of treatment plans to compensate for positional changes of target volumes and organs at risk (OARs). However, current adaptation times are relatively long an
Externí odkaz:
https://doaj.org/article/d9c2199343314d6fac4b36a228460337
Autor:
Robert Olson, Hadassah Abraham, Curtis Leclerc, Alexander Benny, Sarah Baker, Quinn Matthews, Nick Chng, Alanah Bergman, Benjamin Mou, Emma M. Dunne, Devin Schellenberg, Will Jiang, Elisa Chan, Siavash Atrchian, Shilo Lefresne, Hannah Carolan, Boris Valev, Scott Tyldesley, Andrew Bang, Tanya Berrang, Haley Clark, Fred Hsu, Alexander V. Louie, Andrew Warner, David A. Palma, Doris Howell, Aisling Barry, Laura Dawson, Petra Grendarova, Debra Walker, Rishi Sinha, Jillian Tsai, Houda Bahig, Isabelle Thibault, Rashmi Koul, Sashendra Senthi, Iain Phillips, Derek Grose, Paul Kelly, John Armstrong, Ronan McDermott, Candice Johnstone, Srini Vasan, Noel Aherne, Stephen Harrow, Mitchell Liu
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Radiotherapy delivery regimens can vary between a single fraction (SF) and multiple fractions (MF) given daily for up to several weeks depending on the location of the cancer or metastases. With limited evidence comparing fraction
Externí odkaz:
https://doaj.org/article/4f87355d9b904d85b0fb9be81c1c6304
Autor:
Muhammad Ali, Kendrick Koo, David Chang, Phil Chan, Sheng F. Oon, Daniel Moon, Declan G. Murphy, Renu Eapen, Jeremy Goad, Nathan Lawrentschuk, Arun A. Azad, Sarat Chander, Mark Shaw, Nicholas Hardcastle, Shankar Siva
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-9 (2024)
Abstract Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment for patients with primary renal cell carcinoma (RCC). However, its impact on renal function is unclear. This study aimed to evaluate incidence and clinical fa
Externí odkaz:
https://doaj.org/article/08cdee63f1d54833baeea559c883b2c1
Publikováno v:
Current Oncology, Vol 30, Iss 12, Pp 10283-10298 (2023)
Stereotactic ablative radiotherapy (SABR) has challenged the conventional wisdom surrounding the radioresistance of renal cell carcinoma (RCC). In the past decade, there has been a significant accumulation of clinical data to support the safety and e
Externí odkaz:
https://doaj.org/article/7046ba6749964f33b1302608bfa2632d
Autor:
Ciro Franzese, Panagiotis Balermpas
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 46, Iss , Pp 100766- (2024)
Introduction: Although stereotactic ablative radiotherapy (SABR) has advance to standard-of-care for many different indications like lung and liver malignancies, it still remains in its infancy for treating head and neck cancer. Nevertheless there is
Externí odkaz:
https://doaj.org/article/07750d5444a84b068e82f64f3b27b31e